Cabot (NYSE:CBT - Get Free Report) is expected to issue its Q4 2026 results after the market closes on Monday, November 2nd. Analysts expect Cabot to announce earnings of $1.55 per share and revenue of $927.29 million for the quarter. Cabot has set its FY 2026 guidance at 6.150-6.450 EPS. Individuals are encouraged to explore the company's upcoming Q4 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.
Cabot (NYSE:CBT - Get Free Report) last issued its earnings results on Monday, August 3rd. The specialty chemicals company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.66 by $0.01. Cabot had a return on equity of 20.29% and a net margin of 5.23%. The company had revenue of $982.00 million during the quarter, compared to the consensus estimate of $943.16 million. During the same period last year, the business posted $1.90 EPS. The firm's revenue for the quarter was up 6.4% compared to the same quarter last year. On average, analysts expect Cabot to post $6.35 EPS for the current fiscal year and $7.08 EPS for the next fiscal year.
Cabot Stock Performance
Shares of Cabot stock opened at $73.86 on Monday. Cabot has a one year low of $58.33 and a one year high of $94.53. The firm has a market capitalization of $3.81 billion, a price-to-earnings ratio of 20.80, a PEG ratio of 8.69 and a beta of 0.83. The business has a 50-day simple moving average of $79.05 and a 200 day simple moving average of $82.49. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 0.97.
Insiders Place Their Bets
In other Cabot news, CEO Sean Keohane sold 134,895 shares of Cabot stock in a transaction on Friday, August 28th. The shares were sold at an average price of $85.00, for a total transaction of $11,466,075.00. Following the transaction, the chief executive officer directly owned 404,134 shares of the company's stock, valued at $34,351,390. The trade was a 25.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 229,597 shares of company stock worth $19,646,746. 3.08% of the stock is currently owned by company insiders.
Analyst Ratings Changes
CBT has been the topic of several recent research reports. Wall Street Zen upgraded Cabot from a "hold" rating to a "buy" rating in a report on Sunday, October 11th. Weiss Ratings reissued a "hold (c)" rating on shares of Cabot in a research note on Friday, August 21st. JPMorgan Chase & Co. boosted their price objective on Cabot from $70.00 to $78.00 and gave the company an "underweight" rating in a report on Friday, August 7th. UBS Group lowered their target price on Cabot from $92.00 to $86.00 and set a "neutral" rating on the stock in a research report on Monday, October 5th. Finally, Truist Financial set a $100.00 target price on Cabot in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Cabot has a consensus rating of "Hold" and a consensus target price of $87.80.
Check Out Our Latest Analysis on Cabot
About Cabot
(
Get Free Report)
Cabot Corporation NYSE: CBT is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company develops and manufactures materials used to improve the performance, durability, conductivity, color and purity of products across a range of industries.
Cabot's products include carbon black used in tires, rubber goods, coatings, plastics and printing inks; specialty carbons and conductive materials for batteries and other applications; and specialty compounds and masterbatches.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cabot, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabot wasn't on the list.
While Cabot currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.